Biocollection for patients with Myelodysplastic Syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect biological samples from patients diagnosed with Myelodysplastic Syndromes (MDS) to support three scientific projects focused on understanding the disease's pathophysiology. One of the key projects investigates splicing anomalies in MDS patients with SF3B1 mutations, which are prevalent in this population. By analyzing RNA sequences, researchers hope to uncover the functional implications of these mutations and their role in the formation of specific blood cell types. The study will involve patients managed at the Cancer-Hematology Institute of the Brest CHRU.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major
* patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and/or during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU
* Presence of biological material collected within the CRB
* Patient's consent obtained

Exclusion Criteria :

* Minor and pregnant woman
* Lack of biological material collected within the CRB
* Refusal to participate: lack of consent - Unable to consent
* Patient under judicial protection: guardianship, curatorship ...

Where it's running

• Chu Brest
  Brest, France Recruiting

Study contacts

• Principal investigator: Nathalie Douet-Guilbert, MD,PhD — Chru Brest
• Study coordinator: Nathalie Douet-Guilbert, MD, PhD
• Email: nathalie.douet-guilbert@chu-brest.fr
• Phone: +33229020215

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.